Hepatic steatosis in adults on CFTR modulators is commonly associated with cardiometabolic criteria consistent with metabolic dysfunction-associated steatotic liver disease

Sofia Manioudaki

doi:10.1016/j.jcf.2026.06.008

Hepatic steatosis in adults on CFTR modulators is commonly associated with cardiometabolic criteria consistent with metabolic dysfunction-associated steatotic liver disease

2026-07-01

0

PRE

AI

S

Sofia Manioudaki

L

Larisa Vasilieva

E

Eleni Geladari

I

Iliana Mani

V

Vassilios Sevastianos

F

Filia Diamantea

Α

Αlexandra Alexopoulou *

DOI：10.1016/j.jcf.2026.06.008

Original

Original request for help

Save

Abstract

En 中文

• In pwCF receiving treatment, BMI increased significantly during a 2-year follow-up. • Increased body weight is an independent predictor of hepatic steatosis. • Weight gain did not necessarily lead to hepatic steatosis. • Liver stiffness improves in pwCF receiving CFTR modulators. • Most pwCF with HS exhibit cardiometabolic features consistent with MASLD.

Hepatic steatosis in adults on CFTR modulators is commonly associated with cardiometabolic criteria consistent with metabolic dysfunction-associated steatotic liver disease

Abstract

Journal

Organization

Cited Papers

Citing Papers